Pico-Tesla commences placebo-controlled Magneceutical Therapy study for Alzheimer's disease

Pico-Tesla, The Magneceutical^® Company, announced that it has commenced a randomized, double-blind, placebo-controlled pilot study of 30 patients who have Alzheimer's disease symptoms. The pilot study seeks to determine whether the application of magnetic fields generated by Pico-Tesla's patented Resonator™ system can be effective as an adjunctive therapy to oral medications in reducing the symptoms of Alzheimer's disease.

“We are very pleased to have Dr. Amanda Smith coordinating this important study that may help to explore the clinical potential of Magneceutical® Therapy for Alzheimer's patients”

The study will be coordinated by Amanda Grant Smith, M.D., Medical Director of the USF Health Byrd Alzheimer's Institute, University of South Florida (USF).

"We are very pleased to have Dr. Amanda Smith coordinating this important study that may help to explore the clinical potential of Magneceutical® Therapy for Alzheimer's patients," said Allen Braswell, CEO of Pico-Tesla.

Dr. Smith received her undergraduate degree from Emory University in 1992 and her medical degree from Jefferson Medical College in 1997. She did her internship, residency in psychiatry, and fellowship in geriatric psychiatry at the University of South Florida College of Medicine. Dr. Smith is a Diplomate of the American Board of Psychiatry and Neurology, with subspecialty certification in geriatric psychiatry. She is a member of the American Association for Geriatric Psychiatry and a charter member of ISTAART, the International Society to Advance Alzheimer Research and Treatment.

Pico-Tesla's Magneceutical^® Therapy involves the use of an extremely low-level electromagnetic field (EMF) applied by a specially designed device—the Resonator™, invented by Dr. Jerry I. Jacobson, along with proprietary therapeutic protocols—and is currently in clinical trials to determine its effectiveness for improving the signs and symptoms of several diseases, including Alzheimer's disease, atrial fibrillation, Parkinson's disease, fibromyalgia and osteoarthritis.